Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
life sciences
national
7
×
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
7
×
texas blog main
7
×
texas top stories
wisconsin blog main
wisconsin top stories
biotech
indiana blog main
indiana top stories
fda
cancer
ceo
clinical trials
commissioner
gene editing
immunotherapy
ipo
lung cancer
merck
roche
scott gottlieb
shutdown
What
medicine
7
×
cancer
bio
drug
roundup
fda
genetic
new
study
alzheimer's
approved
ask
bad
big
biopharma
bosley's
bosley’s
brain
bridge
bucks
car
cas
case
celgene
centers
ceo
colleagues
congrats
crime
crispr
cut
deeper
departure
depression
disease
dna
doses
editas
effect
eisai
Language
unset
Current search:
national
×
" texas blog main "
×
medicine
×
" seattle top stories "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More
@xconomy.com
5 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
6 years ago
Will New Study Cut Guesswork for Depression Medicine Prescriptions?